

Sean P David

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4752003/publications.pdf>

Version: 2024-02-01

78
papers

5,233
citations

126708

33
h-index

98622

67
g-index

83
all docs

83
docs citations

83
times ranked

8898
citing authors

#	ARTICLE	IF	CITATIONS
1	Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. <i>Nature Genetics</i> , 2019, 51, 237-244.	9.4	1,307
2	Clinical Interpretation and Implications of Whole-Genome Sequencing. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1035.	3.8	398
3	Publication and other reporting biases in cognitive sciences: detection, prevalence, and prevention. <i>Trends in Cognitive Sciences</i> , 2014, 18, 235-241.	4.0	361
4	Ventral Striatum/Nucleus Accumbens Activation to Smoking-Related Pictorial Cues in Smokers and Nonsmokers: A Functional Magnetic Resonance Imaging Study. <i>Biological Psychiatry</i> , 2005, 58, 488-494.	0.7	259
5	A Functional Genetic Variation of the Serotonin (5-HT) Transporter Affects 5-HT1A Receptor Binding in Humans. <i>Journal of Neuroscience</i> , 2005, 25, 2586-2590.	1.7	253
6	Molecular Genetics of Successful Smoking Cessation. <i>Archives of General Psychiatry</i> , 2008, 65, 683.	13.8	227
7	Phased Whole-Genome Genetic Risk in a Family Quartet Using a Major Allele Reference Sequence. <i>PLoS Genetics</i> , 2011, 7, e1002280.	1.5	137
8	PharmGKB summary. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 695-708.	0.7	114
9	Chronic cigarette smoking and the microstructural integrity of white matter in healthy adults: A diffusion tensor imaging study. <i>Nicotine and Tobacco Research</i> , 2008, 10, 137-147.	1.4	111
10	Potential Reporting Bias in fMRI Studies of the Brain. <i>PLoS ONE</i> , 2013, 8, e70104.	1.1	110
11	Potential Reporting Bias in Neuroimaging Studies of Sex Differences. <i>Scientific Reports</i> , 2018, 8, 6082.	1.6	109
12	Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. <i>Nicotine and Tobacco Research</i> , 2007, 9, 821-833.	1.4	89
13	Effects of Acute Nicotine Abstinence on Cue-elicited Ventral Striatum/Nucleus Accumbens Activation in Female Cigarette Smokers: A Functional Magnetic Resonance Imaging Study. <i>Brain Imaging and Behavior</i> , 2007, 1, 43-57.	1.1	89
14	Association of the DRD2 gene Taq1A polymorphism and smoking behavior: A meta-analysis and new data. <i>Nicotine and Tobacco Research</i> , 2009, 11, 64-76.	1.4	86
15	Meta-analysis of up to 622,409 individuals identifies 40 novel smoking behaviour associated genetic loci. <i>Molecular Psychiatry</i> , 2020, 25, 2392-2409.	4.1	83
16	Bupropion Efficacy for Smoking Cessation is Influenced by the DRD2 Taq1A Polymorphism: Analysis of Pooled Data from two Clinical Trials. <i>Nicotine and Tobacco Research</i> , 2007, 9, 1251-1257.	1.4	74
17	Smoking and Genetic Risk Variation Across Populations of European, Asian, and African American Ancestry: A Meta-Analysis of Chromosome 15q25. <i>Genetic Epidemiology</i> , 2012, 36, 340-351.	0.6	69
18	Exome Chip Meta-analysis Fine Maps Causal Variants and Elucidates the Genetic Architecture of Rare Coding Variants in Smoking and Alcohol Use. <i>Biological Psychiatry</i> , 2019, 85, 946-955.	0.7	69

#	ARTICLE	IF	CITATIONS
19	Opioid antagonists for smoking cessation. The Cochrane Library, 2013, , CD003086.	1.5	62
20	Are there sex differences in transdermal nicotine replacement therapy patch efficacy? A meta-analysis. Nicotine and Tobacco Research, 2004, 6, 769-776.	1.4	59
21	Association of COMT Val108/158Met Genotype with Smoking Cessation in a Nicotine Replacement Therapy Randomized Trial. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1065-1069.	1.1	58
22	The neuroeconomics of nicotine dependence: A preliminary functional magnetic resonance imaging study of delay discounting of monetary and cigarette rewards in smokers. Psychiatry Research - Neuroimaging, 2012, 202, 20-29.	0.9	58
23	The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: Follow-up of a randomized controlled trial. Nicotine and Tobacco Research, 2007, 9, 225-231.	1.4	56
24	Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?. Nicotine and Tobacco Research, 2003, 5, 935-942.	1.4	53
25	Evidence of reporting biases in voxel-based morphometry (VBM) studies of psychiatric and neurological disorders. Human Brain Mapping, 2014, 35, 3052-3065.	1.9	50
26	No association between functional catechol O-methyl transferase 1947A>G polymorphism and smoking initiation, persistent smoking or smoking cessation. Pharmacogenetics and Genomics, 2002, 12, 265-268.	5.7	48
27	Genome-wide association for smoking cessation success: participants in the Patch in Practice trial of nicotine replacement. Pharmacogenomics, 2010, 11, 357-367.	0.6	47
28	Associations of CYP2A6 genotype with smoking behaviors in southern China. Addiction, 2011, 106, 985-994.	1.7	46
29	Association between CHRNA5 genetic variation at rs16969968 and brain reactivity to smoking images in nicotine dependent women. Drug and Alcohol Dependence, 2012, 120, 7-13.	1.6	45
30	Opioid antagonists for smoking cessation. , 2006, , CD003086.		41
31	Effects of nicotine withdrawal on verbal working memory and associated brain response. Psychiatry Research - Neuroimaging, 2010, 183, 69-74.	0.9	40
32	A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation. Nicotine and Tobacco Research, 2008, 10, 231-240.	1.4	34
33	Making Personalized Health Care Even More Personalized: Insights From Activities of the IOM Genomics Roundtable. Annals of Family Medicine, 2015, 13, 373-380.	0.9	34
34	Teaching Medical Students to Help Patients Quit Smoking: Outcomes of a 10-School Randomized Controlled Trial. Journal of General Internal Medicine, 2016, 31, 172-181.	1.3	34
35	Genetic variation in the dopamine pathway and smoking cessation. Pharmacogenomics, 2008, 9, 1307-1321.	0.6	33
36	Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. Addiction, 2013, 108, 2202-2211.	1.7	30

#	ARTICLE	IF	CITATIONS
37	Interaction between heavy smoking and CYP2A6 genotypes on type 2 diabetes and its possible pathways. <i>European Journal of Endocrinology</i> , 2011, 165, 961-967.	1.9	29
38	Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. <i>The Cochrane Library</i> , 2018, 2018, CD011823.	1.5	28
39	Genetic variation in the serotonin pathway and smoking cessation with nicotine replacement therapy: New data from the Patch in Practice trial and pooled analyses. <i>Drug and Alcohol Dependence</i> , 2008, 98, 77-85.	1.6	27
40	Systematic review and meta-analysis of opioid antagonists for smoking cessation. <i>BMJ Open</i> , 2014, 4, e004393.	0.8	26
41	Pharmacogenetics of Smoking Cessation in General Practice: Results From the Patch II and Patch in Practice Trials. <i>Nicotine and Tobacco Research</i> , 2011, 13, 157-167.	1.4	24
42	Sex differences in TTC12/ANKK1 haplotype associations with daily tobacco smoking in Black and White Americans. <i>Nicotine and Tobacco Research</i> , 2010, 12, 251-262.	1.4	22
43	Implementing Primary Care Mediated Population Genetic Screening Within an Integrated Health System. <i>Journal of the American Board of Family Medicine</i> , 2021, 34, 861-865.	0.8	20
44	Extended treatment for cigarette smoking cessation: a randomized control trial. <i>Addiction</i> , 2017, 112, 1451-1459.	1.7	19
45	LetterComment on "The public health implications of smoking-induced decreased serum and red blood cell folate levels". <i>Nicotine and Tobacco Research</i> , 2003, 5, 397-399.	1.4	18
46	Teaching tobacco dependence treatment and counseling skills during medical school: Rationale and design of the Medical Students helping patients Quit tobacco (MSQuit) group randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2014, 37, 284-293.	0.8	18
47	Patient and provider perspectives on the development of personalized medicine: a mixed-methods approach. <i>Journal of Community Genetics</i> , 2018, 9, 283-291.	0.5	17
48	Pharmacogenetic Smoking Cessation Intervention in a Health Care Setting: A Pilot Feasibility Study. <i>Nicotine and Tobacco Research</i> , 2013, 15, 518-526.	1.4	16
49	The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings. <i>Nicotine and Tobacco Research</i> , 2018, 20, 403-413.	1.4	16
50	From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation. <i>Pharmacogenomics</i> , 2018, 19, 861-871.	0.6	16
51	Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How. <i>Nicotine and Tobacco Research</i> , 2018, 20, 414-424.	1.4	15
52	Medical school curriculum characteristics associated with intentions and frequency of tobacco dependence treatment among 3rd year U.S. medical students. <i>Preventive Medicine</i> , 2015, 72, 56-63.	1.6	14
53	Smoking behavior and association of melanoma and nonmelanoma skin cancer in the Women's Health Initiative. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 190-191.e3.	0.6	14
54	Tobacco dependence treatment teaching by medical school clerkship preceptors: Survey responses from more than 1000 US medical students. <i>Preventive Medicine</i> , 2013, 57, 81-86.	1.6	12

#	ARTICLE	IF	CITATIONS
55	Gene by Environment Investigation of Incident Lung Cancer Risk in African-Americans. EBioMedicine, 2016, 4, 153-161.	2.7	12
56	Relationship Between Amounts of Daily Cigarette Consumption and Abdominal Obesity Moderated by CYP2A6 Genotypes in Chinese Male Current Smokers. Annals of Behavioral Medicine, 2012, 43, 253-261.	1.7	11
57	Effects of Nicotine Deprivation and Replacement on BOLD-fMRI Response to Smoking Cues as a Function of DRD4 VNTR Genotype. Nicotine and Tobacco Research, 2014, 16, 939-947.	1.4	11
58	Chronic psychosocial stressors and salivary biomarkers in emerging adults. Psychoneuroendocrinology, 2012, 37, 1158-1170.	1.3	10
59	Investigating subgroups in smoking cessation treatment response: Response to Perkins. Nicotine and Tobacco Research, 2004, 6, 865-867.	1.4	9
60	Retrospective analysis of changing characteristics of treatment-seeking smokers: implications for further reducing smoking prevalence. BMJ Open, 2016, 6, e010960.	0.8	8
61	Pharmacogenetics. Primary Care - Clinics in Office Practice, 2004, 31, 543-559.	0.7	6
62	No association between germline variation in catechol-O-methyltransferase and colorectal cancer survival in postmenopausal women. Menopause, 2014, 21, 415-420.	0.8	5
63	Smoking Cessation Pharmacotherapy Based on Genetically-Informed Biomarkers: What is the Evidence?. Nicotine and Tobacco Research, 2019, 21, 1289-1293.	1.4	5
64	Persistent alterations of gene expression profiling of human peripheral blood mononuclear cells from smokers. Molecular Carcinogenesis, 2016, 55, 1424-1437.	1.3	4
65	The Contribution of Pharmacogenetic Drug Interactions to 90-Day Hospital Readmissions: Preliminary Results from a Real-World Healthcare System. Journal of Personalized Medicine, 2021, 11, 1242.	1.1	4
66	Smoking cessation in primary care. BMJ: British Medical Journal, 2008, 336, 1200-1201.	2.4	3
67	Commentary on <sc>C</sc>hen <i>et al</i>. (2014): Another step on the road to clinical utility of pharmacogenetics for smoking cessation?. Addiction, 2014, 109, 138-139.	1.7	3
68	Differential Efficacy of Nicotine Replacement Among Overweight and Obese Women Smokers. Nicotine and Tobacco Research, 2015, 17, 855-861.	1.4	3
69	Application of Functional Neuroimaging to Examination of Nicotine Dependence. , 2011, , 117-145.		3
70	Smoking cessation. BMJ: British Medical Journal, 2008, 336, 217-217.	2.4	2
71	Tobacco Genomics: Complexity and Translational Challenges. Nicotine and Tobacco Research, 2019, 21, 705-706.	1.4	2
72	Does providing hereditary breast cancer risk assessment support to practicing physicians decrease the likelihood of them discussing such risk with their patients?. Genetics in Medicine, 2004, 6, 542-542.	1.1	1

#	ARTICLE	IF	CITATIONS
73	SUCCESSFUL LATINO COMMUNITY PARTNERSHIP PROGRAM FOR SMOKING CESSATION. American Journal of Public Health, 2007, 97, 1348-1349.	1.5	1
74	Novel Methodologies and the Need for Big Data in Nicotine and Tobacco Genetics Research. Nicotine and Tobacco Research, 2017, 19, 385-386.	1.4	1
75	Clinical and Personal Utility of Genetic Risk Testing. American Family Physician, 2018, 97, 600-602.	0.1	1
76	Effect Modification by Social Determinants of Pharmacogenetic Medication Interactions on 90-Day Hospital Readmissions within an Integrated U.S. Healthcare System. Journal of Personalized Medicine, 2022, 12, 1145.	1.1	1
77	Gene by Environment Interaction Linking the Chromosome 15q25 Locus with Cigarette Consumption and Lung Cancer Susceptibility - Are African American Affected Differently? "Authors' Reply. EBioMedicine, 2016, 4, 15.	2.7	0
78	Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. The Cochrane Library, 2021, 2021, CD011823.	1.5	0